Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

Heppner, D. Gray; Kemp, Tracy; Nichols, Richard A.; Dasen, Emily J; Link, Charles J.; Xu, Zhi Jin; Sheldon, Eric; Monath, Thomas P.; Kemp, TL; Martin, Brian K.; Ramsey, W. Jay; Fusco, Joan; Crowell, Joseph; Creager, J; Das, Rituparna; Xu, Zeyuan; Klein, Richard J.T.; Nowak, Teresa; Gerstenberger, Eric; Bliss, Robin; Ea, Sheldon; Ra, Feldman; Essink, Brandon; Smith, William B.; Chu, Laurence; Seger, WM; Saleh, Jamshid; Borders, JL; Adams, Malcolm

doi:10.1016/s1473-3099(17)30313-4

Cited by 103 publications

(108 citation statements)

References 27 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7 The incidence of arthritis in the other phase 1, 2, and 3 trials of rVSV-ZEBOV has been lower (<5%) across a large dose range, including doses of 1 × 10⁸ pfu or higher. 2,7,8,10,11,29 A multivariate analysis indicated female sex (OR 2·2, 95% CI 1·1–4·1) and a medical history of arthritis (2·8, 1·3–6·2) as risk factors for the development of arthritis post vaccination. This analysis was done on results from a study conducted in the USA, Spain, and Canada with 1197 participants, 7 and the analysis is now mentioned in the investigator’s brochure of the rVSV-ZEBOV vaccine.…”

mentioning

confidence: 99%

Prevention of Ebola virus disease through vaccination: where we are in 2018

et al. 2018

View full text Add to dashboard Cite

mentioning

confidence: 99%

Prevention of Ebola virus disease through vaccination: where we are in 2018

et al. 2018

View full text Add to dashboard Cite

“…Current vaccine candidates may also not provide the long-term protective immunity (≥10 years) necessary for sustainable protection against spillover events from animal reservoirs. Two studies reported immune responses 12 months after vaccination with different Ebola virus vaccine candidates (34,35). One of them described seroconversion in >90% of individuals after a single injection of rVSV-ZEBOV, a vesicular stomatitis virus-based Ebola virus vaccine.…”

Section: Discussionmentioning

confidence: 99%

Herd Immunity to Ebolaviruses is not a Realistic Target for Current Vaccination Strategies

Masterson

Lobel

Carroll

et al. 2018

Preprint

View full text Add to dashboard Cite

22The recent West African Ebola virus pandemic, which affected >28,000 individuals increased 23 interest in anti-Ebolavirus vaccination programs. Here, we systematically analyzed the 24 requirements for a prophylactic vaccination program based on the basic reproductive number 25 (R0, i.e. the number of secondary cases that result from an individual infection). Published R0 26 values were determined by a systematic literature research and ranged from 0.37 to 20. R0s 27 ≥4 realistically reflected the critical early outbreak phases and superspreading events. Based 28 on the R0, the herd immunity threshold (Ic) was calculated using the equation Ic=1-(1/R0). 29The critical vaccination coverage (Vc) needed to provide herd immunity was determined by 30 including the vaccine effectiveness (E) using the equation Vc=Ic/E. At an R0 of 4, the Ic is 31 75% and at an E of 90%, more than 80% of a population need to be vaccinated to establish 32 herd immunity. Such vaccination rates are currently unrealistic because of resistance against 33 vaccinations, financial/ logistical challenges, and a lack of vaccines that provide long-term 34 protection against all human-pathogenic Ebolaviruses. Hence, outbreak management will for 35 the foreseeable future depend on surveillance and case isolation. Clinical vaccine candidates 36 are only available for Ebola viruses. Their use will need to be focused on health care workers, 37 potentially in combination with ring vaccination approaches. 38 39

show abstract

“…Second, despite replicating to high titres in several cell lines, as a negative-sense RNA virus, rescue of recombinant VSV from plasmid DNA can be cumbersome-requiring co-transfection of five plasmids into a permissive cell line [90,91]. Finally, the reactogenicity of VSV-vectored vaccines may pose a concern; in phase I trials of VSVΔG/EBOVGP, high incidence of fever, headache, chills, fatigue, and myalgia was observed after immunisation [92,93].…”

Section: Vesicular Stomatitis Virus Vector Platformmentioning

confidence: 99%

Vaccine platforms for the prevention of Lassa fever

2019

View full text Add to dashboard Cite

A B S T R A C TLassa fever is an acute viral haemorrhagic illness caused by Lassa virus (LASV), which is endemic throughout much of West Africa. The virus primarily circulates in the Mastomys natalensis reservoir and is transmitted to humans through contact with infectious rodents or their secretions; human-to-human transmission is documented as well. With the exception of Dengue fever, LASV has the highest human impact of any haemorrhagic fever virus. On-going outbreaks in Nigeria have resulted in unprecedented mortality. Consequently, the World Health Organization (WHO) has listed LASV as a high priority pathogen for the development of treatments and prophylactics. Currently, there are no licensed vaccines to protect against LASV infection. Although numerous candidates have demonstrated efficacy in animal models, to date, only a single candidate has advanced to clinical trials. Lassa fever vaccine development efforts have been hindered by the high cost of biocontainment requirements, the absence of established correlates of protection, and uncertainty regarding the extent to which animal models are predictive of vaccine efficacy in humans. This review briefly discusses the epidemiology and biology of LASV infection and highlights recent progress in vaccine development.

show abstract

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

Cited by 103 publications

References 27 publications

Prevention of Ebola virus disease through vaccination: where we are in 2018

Prevention of Ebola virus disease through vaccination: where we are in 2018

Herd Immunity to Ebolaviruses is not a Realistic Target for Current Vaccination Strategies

Vaccine platforms for the prevention of Lassa fever

Contact Info

Product

Resources

About